Mid-Term Outcomes Following Percutaneous Pulmonary Valve Implantation Using the "Folded Melody Valve" Technique.
Adolescent
Adult
Cardiac Catheterization
/ adverse effects
Child
Child, Preschool
Female
Heart Valve Prosthesis
Heart Valve Prosthesis Implantation
/ adverse effects
Humans
Male
Middle Aged
Prosthesis Design
Pulmonary Valve
/ diagnostic imaging
Pulmonary Valve Insufficiency
/ diagnostic imaging
Retrospective Studies
Treatment Outcome
Young Adult
incidence
probability
pulmonary valve
retrospective
stent
Journal
Circulation. Cardiovascular interventions
ISSN: 1941-7632
Titre abrégé: Circ Cardiovasc Interv
Pays: United States
ID NLM: 101499602
Informations de publication
Date de publication:
04 2021
04 2021
Historique:
pubmed:
18
3
2021
medline:
16
10
2021
entrez:
17
3
2021
Statut:
ppublish
Résumé
The folded valve is a manual shortening of the Melody device, which has been validated as a valuable therapeutic option for the management of dysfunctional right ventricular outflow tracts needing a short valved stent. In this article, we aimed to evaluate, in a multicenter cohort, the mid-term outcomes of patients in whom a percutaneous pulmonary valve implantation was performed using the folded valve technique. A 2012 to 2018 retrospective multicenter study was performed in 7 European institutions. All patients who benefit from percutaneous pulmonary valve implantation with a folded Melody valve were included. A total of 49 patients (median age, 19 years [range 4–56], 63% male) were included. The primary percutaneous pulmonary valve implantation indication was right ventricular outflow tract stenosis (n=19; 39%), patched native right ventricular outflow tracts were the most common substrate (n=15; 31%). The folded technique was mostly used in short right ventricular outflow tracts (n=28; 57%). Procedural success was 100%. After a median follow-up of 28 months (range, 4–80), folded Melody valve function was comparable to the immediate postimplantation period (mean transvalvular peak velocity=2.6±0.6 versus 2.4±0.6 m/s, P>0.1; only 2 patients had mild pulmonary regurgitation). Incidence rate of valve-related reinterventions was 2.1% per person per year (95% CI, 0.1%–3.9%). The probability of survival without valve-related reinterventions at 36 months was 90% (95% CI, 76%–100%). The folded Melody valve is a safe technique with favorable mid-term outcomes up to 6.5 years after implantation, comparable with the usual Melody valve implantation procedure. Complications and reinterventions rates were low, making this technique relevant in selected patients.
Sections du résumé
BACKGROUND
The folded valve is a manual shortening of the Melody device, which has been validated as a valuable therapeutic option for the management of dysfunctional right ventricular outflow tracts needing a short valved stent. In this article, we aimed to evaluate, in a multicenter cohort, the mid-term outcomes of patients in whom a percutaneous pulmonary valve implantation was performed using the folded valve technique.
METHODS
A 2012 to 2018 retrospective multicenter study was performed in 7 European institutions. All patients who benefit from percutaneous pulmonary valve implantation with a folded Melody valve were included.
RESULTS
A total of 49 patients (median age, 19 years [range 4–56], 63% male) were included. The primary percutaneous pulmonary valve implantation indication was right ventricular outflow tract stenosis (n=19; 39%), patched native right ventricular outflow tracts were the most common substrate (n=15; 31%). The folded technique was mostly used in short right ventricular outflow tracts (n=28; 57%). Procedural success was 100%. After a median follow-up of 28 months (range, 4–80), folded Melody valve function was comparable to the immediate postimplantation period (mean transvalvular peak velocity=2.6±0.6 versus 2.4±0.6 m/s, P>0.1; only 2 patients had mild pulmonary regurgitation). Incidence rate of valve-related reinterventions was 2.1% per person per year (95% CI, 0.1%–3.9%). The probability of survival without valve-related reinterventions at 36 months was 90% (95% CI, 76%–100%).
CONCLUSIONS
The folded Melody valve is a safe technique with favorable mid-term outcomes up to 6.5 years after implantation, comparable with the usual Melody valve implantation procedure. Complications and reinterventions rates were low, making this technique relevant in selected patients.
Identifiants
pubmed: 33726503
doi: 10.1161/CIRCINTERVENTIONS.120.009707
pmc: PMC8055198
doi:
Types de publication
Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e009707Références
Arch Cardiovasc Dis. 2014 Nov;107(11):635-42
pubmed: 25241221
EuroIntervention. 2014 Feb;9(10):1237-40
pubmed: 24561739
Can J Cardiol. 2018 Jun;34(6):812.e5-812.e7
pubmed: 29801748
Eur Heart J. 2019 Jul 14;40(27):2255-2264
pubmed: 31005985
Circulation. 2015 Jun 2;131(22):1960-70
pubmed: 25944758
Circ Cardiovasc Interv. 2017 Feb;10(2):
pubmed: 28153843
Circ Cardiovasc Interv. 2011 Dec 1;4(6):602-14
pubmed: 22075927
JACC Cardiovasc Interv. 2017 Sep 11;10(17):1746-1759
pubmed: 28823778
Arch Cardiovasc Dis. 2018 Aug - Sep;111(8-9):497-506
pubmed: 29530718
Heart Rhythm. 2016 Nov;13(11):2135-2141
pubmed: 27453127
Circ Cardiovasc Interv. 2014 Jun;7(3):374-80
pubmed: 24867892
Lancet. 2000 Oct 21;356(9239):1403-5
pubmed: 11052583
Circ Cardiovasc Interv. 2014 Apr;7(2):142-8
pubmed: 24569596
EuroIntervention. 2017 Sep 24;13(AA):AA60-AA67
pubmed: 28942387
Circ Cardiovasc Interv. 2012 Dec;5(6):862-70
pubmed: 23212395
JACC Cardiovasc Interv. 2018 Oct 8;11(19):1909-1916
pubmed: 30219326
JACC Cardiovasc Interv. 2020 Feb 10;13(3):e21-e22
pubmed: 31734303
JACC Cardiovasc Interv. 2017 Jul 24;10(14):1449-1458
pubmed: 28728659
Circ Cardiovasc Interv. 2015 Feb;8(2):e002260
pubmed: 25652320
Circulation. 2010 Aug 3;122(5):507-16
pubmed: 20644013
Circ Cardiovasc Interv. 2018 Nov;11(11):e007145
pubmed: 30571200
Int J Cardiol. 2015 Nov 1;198:201-5
pubmed: 26173058
JACC Cardiovasc Interv. 2018 Oct 8;11(19):1920-1929
pubmed: 30286853
Catheter Cardiovasc Interv. 2015 Mar;85(4):604-10
pubmed: 25413082
Circulation. 2007 Mar 20;115(11):1392-7
pubmed: 17339542